Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148843 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
A Phase 2 study, sponsored by Johns Hopkins University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT07148843: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT07148843 is a Phase 2 study that has not yet begun recruiting, run by Johns Hopkins University. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07148843, a Phase 2 study, has not yet begun recruiting, sponsored by Johns Hopkins University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. Adult participants with moderate-to-severe AUD will be admitted to an inpatient research unit at the Johns Hopkins Hospital for a 5-day, 4-night stay that includes alcohol abstinence with management of their alcohol withdrawal. In addition to standard care, participants will receive CBD or placebo (no CBD), complete assessments of withdrawal, sleep quality and provide breath and blood samples.
Interventions
- DRUG Placebo
- DRUG Cannabidiol (CBD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2030-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148843
The ClinicalTrials.gov registry entry for NCT07148843 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07148843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07148843 about?
NCT07148843 is a clinical study titled "Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving". Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of thes...
What is the current status of trial NCT07148843?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2026-08-01. Estimated completion is 2030-10-31.
What interventions are being tested in trial NCT07148843?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (CBD) (DRUG).
Who is sponsoring clinical trial NCT07148843?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.